JASPER THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
JASPER THERAPEUTICS, INC. (JSPR) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $764.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $764.00K, a 57.95% decline year-over-year.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $423.00K, a 76.64% decline year-over-year.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $1.82M, a 22.60% increase year-over-year.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $1.81M, a 54.92% increase year-over-year.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $6.71M, a 1.42% increase from fiscal 2024.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $6.62M, a 27.02% increase from fiscal 2023.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $5.21M, a 27.38% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $4.09M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $764.00K 10-Q · filed 2026-08-14 | $1.19M 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $423.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $6.71M 10-K · filed 2026-03-30 | |||
| 2025-06-30 | $1.82M 10-Q · filed 2026-08-14 | $3.63M 10-Q · filed 2026-08-14 | $5.60M derived: sum of 3 quarters · filed 2026-08-14 | $7.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.81M 10-Q · filed 2026-05-14 | $3.78M derived: sum of 2 quarters · filed 2026-05-14 | $5.78M derived: sum of 3 quarters · filed 2026-05-14 | $7.26M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.97M derived: sum of 2 quarters · filed 2026-03-30 | $5.45M derived: sum of 3 quarters · filed 2026-03-30 | $6.62M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.00M 10-Q · filed 2024-11-07 | $3.48M derived: sum of 2 quarters · filed 2024-11-07 | $4.65M 10-Q · filed 2024-11-07 | $5.81M derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-06-30 | $1.48M 10-Q · filed 2024-08-13 | $2.65M 10-Q · filed 2024-08-13 | $3.81M derived: sum of 3 quarters · filed 2025-05-12 | $5.20M derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-12 | $2.33M derived: sum of 2 quarters · filed 2025-05-12 | $3.72M derived: sum of 3 quarters · filed 2025-05-12 | $5.11M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.55M derived: sum of 2 quarters · filed 2025-02-28 | $3.94M derived: sum of 3 quarters · filed 2025-02-28 | $5.21M 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-07 | $2.79M derived: sum of 2 quarters · filed 2024-11-07 | $4.05M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.39M 10-Q · filed 2024-08-13 | $2.66M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $1.27M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $4.09M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |